KELLY CRAWFORD: Open Payments
NPI 1588938450 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$468 in 32 payments from 11 companies in 2025. Trend: 2023 $424 · 2024 $398 · 2025 $468
Food & beverage: $468
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $185 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Antares Pharma, Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
| Novo Nordisk Inc | 1 | $16 |
Products named: QULIPTA, UBRELVY, Auvelity, Kerendia, FARXIGA, TRINTELLIX, NEXLETOL, XYOSTED.
Industry payments across LA — which companies pay providers there.
